Literature DB >> 35366062

In vitro modeling of liver fibrosis in 3D microtissues using scalable micropatterning system.

Massoud Vosough1, Andreas Nüssler2, Ensieh Zahmatkesh3,1, Amnah Othman3, Bianca Braun3, Romina Aspera3, Marc Ruoß3, Abbas Piryaei4,5.   

Abstract

Liver fibrosis is the late consequence of chronic liver inflammation which could eventually lead to cirrhosis, and liver failure. Among various etiological factors, activated hepatic stellate cells (aHSCs) are the major players in liver fibrosis. To date, various in vitro liver fibrosis models have been introduced to address biological and medical questions. Availability of traditional in vitro models could not fully recapitulate complicated pathology of liver fibrosis. The purpose of this study was to develop a simple and robust model to investigate the role of aHSCs on the progression of epithelial to mesenchymal transition (EMT) in hepatocytes during liver fibrogenesis. Therefore, we applied a micropatterning approach to generate 3D co-culture microtissues consisted of HepaRG and human umbilical cord endothelial cells (HUVEC) which co-cultured with inactivated LX-2 cells or activated LX-2 cells, respectively, as normal or fibrotic liver models in vitro. The result indicated that the activated LX-2 cells could induce EMT in HepaRG cells through activation of TGF-β/SMAD signaling pathway. Besides, in the fibrotic microtissue, physiologic function of HepaRG cells attenuated compared to the control group, e.g., metabolic activity and albumin secretion. Moreover, our results showed that after treatment with Galunisertib, the fibrogenic properties decreased, in the term of gene and protein expression. In conclusion, it is proposed that aHSCs could lead to EMT in hepatocytes during liver fibrogenesis. Furthermore, the scalable micropatterning approach could provide enough required liver microtissues to prosper our understanding of the mechanisms involved in the progression of liver fibrosis as well as high throughput (HT) drug screening.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  EMT; Hepatic stellate cells; Liver fibrosis model; Liver microtissue; Tissue micropatterning

Mesh:

Year:  2022        PMID: 35366062     DOI: 10.1007/s00204-022-03265-7

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   6.168


  29 in total

1.  High-throughput organ-on-chip platform with integrated programmable fluid flow and real-time sensing for complex tissue models in drug development workflows.

Authors:  H Azizgolshani; J R Coppeta; E M Vedula; E E Marr; B P Cain; R J Luu; M P Lech; S H Kann; T J Mulhern; V Tandon; K Tan; N J Haroutunian; P Keegan; M Rogers; A L Gard; K B Baldwin; J C de Souza; B C Hoefler; S S Bale; L B Kratchman; A Zorn; A Patterson; E S Kim; T A Petrie; E L Wiellette; C Williams; B C Isenberg; J L Charest
Journal:  Lab Chip       Date:  2021-04-20       Impact factor: 6.799

2.  Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model.

Authors:  Seddik Hammad; Elisabetta Cavalcanti; Julia Werle; Maria Lucia Caruso; Anne Dropmann; Antonia Ignazzi; Matthias Philip Ebert; Steven Dooley; Gianluigi Giannelli
Journal:  Arch Toxicol       Date:  2018-05-28       Impact factor: 5.153

Review 3.  Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis.

Authors:  Wei Chen; Aiting Yang; Jidong Jia; Yury V Popov; Detlef Schuppan; Hong You
Journal:  Hepatology       Date:  2020-08       Impact factor: 17.425

4.  Generation of Hepatic Stellate Cells from Human Pluripotent Stem Cells Enables In Vitro Modeling of Liver Fibrosis.

Authors:  Mar Coll; Luis Perea; Ruben Boon; Sofia B Leite; Julia Vallverdú; Inge Mannaerts; Ayla Smout; Adil El Taghdouini; Delia Blaya; Daniel Rodrigo-Torres; Isabel Graupera; Beatriz Aguilar-Bravo; Christophe Chesne; Mustapha Najimi; Etienne Sokal; Juan José Lozano; Leo A van Grunsven; Catherine M Verfaillie; Pau Sancho-Bru
Journal:  Cell Stem Cell       Date:  2018-06-28       Impact factor: 24.633

5.  Cigarette Smoke Induces the Risk of Metabolic Bone Diseases: Transforming Growth Factor Beta Signaling Impairment via Dysfunctional Primary Cilia Affects Migration, Proliferation, and Differentiation of Human Mesenchymal Stem Cells.

Authors:  Romina H Aspera-Werz; Tao Chen; Sabrina Ehnert; Sheng Zhu; Theresa Fröhlich; Andreas K Nussler
Journal:  Int J Mol Sci       Date:  2019-06-14       Impact factor: 5.923

6.  The inhibitor of autophagy SBI-0206965 aggravates atherosclerosis through decreasing myeloid-derived suppressor cells.

Authors:  Bo Wang; Guanjun Dong; Qingqiing Zhang; Fenglian Yan; Zhihua Li; Chunxia Li; Hui Zhang; Qun Ma; Jun Dai; Chuanping Si; Huabao Xiong
Journal:  Exp Ther Med       Date:  2019-12-11       Impact factor: 2.447

Review 7.  Engineering organoids.

Authors:  Moritz Hofer; Matthias P Lutolf
Journal:  Nat Rev Mater       Date:  2021-02-19       Impact factor: 66.308

8.  Assisted Oocyte Activation With Calcium Ionophore Improves Pregnancy Outcomes and Offspring Safety in Infertile Patients: A Systematic Review and Meta-Analysis.

Authors:  Yinghua Shan; Huishan Zhao; Dongmei Zhao; Jianhua Wang; Yuanqing Cui; Hongchu Bao
Journal:  Front Physiol       Date:  2022-01-24       Impact factor: 4.566

Review 9.  Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis.

Authors:  Isabel Fabregat; Daniel Caballero-Díaz
Journal:  Front Oncol       Date:  2018-09-10       Impact factor: 6.244

Review 10.  Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases.

Authors:  Eline Geervliet; Ruchi Bansal
Journal:  Cells       Date:  2020-05-13       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.